Aquestive Therapeutics AQST 深 滬
已收盤 05-08 16:00:00 美东时间
4.32
+0.090
+2.13%
華盛通- 最 高4.36
- 今 開4.25
- 成交量 189.31万股
- 最 低 4.245
- 昨 收 4.23
- 總市值 5.37亿
- 52周最高 7.55
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 2.222
- 委 比 -16.30%
- 總股本 1.24亿
- 歷史最高 20.696
- 量 比 1.58
- 振 幅 2.72%
- 歷史最低 0.618
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics will report Q1 2026 results and business updates after market close on May 13, 2026. A conference call for investors will be held on May 14 at 8:00 a.m. ET. Registration is required to obtain dial-in details. A live webcast and replay will be available on the Investors section of Aquestive's website. The company specializes in innovative pharmaceuticals, including Anaphylm™ and AQST-108, and operates as a CDMO.
05-06 11:00
Aquestive Therapeutics CLO Thomas Zalewski files initial beneficial ownership statement
Aquestive Therapeutics CLO Thomas Zalewski files initial beneficial ownership statement Aquestive Therapeutics Chief Legal Officer Thomas A. Zalewski filed an initial Form 3 on April 10, 2026, reporting holdings as of April 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUB
04-10 21:56
Aquestive Therapeutics Completes In-Person Type A Meeting With FDA Regarding Resubmission Of NDA For Anaphylm Sublingual Film For Treatment Of Type 1 Allergic Reactions, Including Anaphylaxis
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
03-30 19:15
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics announced the receipt of preliminary comments from the FDA following a successful Type A meeting regarding the resubmission of its Anaphylm NDA in Q3 2026. The FDA provided feedback on pharmacokinetic and human factor study designs, with alignment on key elements. The company plans to address all feedback and advance regulatory submissions in Canada and the EU. Anaphylm aims to be the first oral epinephrine treatment for se...
03-30 11:00
Aquestive Therapeutics Announces Key Legal Leadership Transition
Aquestive Therapeutics ( ($AQST) ) just unveiled an announcement. On March 16, ...
03-20 19:57
Aquestive Therapeutics names Thomas A. Zalewski chief legal and compliance officer
Aquestive Therapeutics names Thomas A. Zalewski chief legal and compliance officer Thomas Zalewski was appointed chief legal officer and chief compliance officer at Aquestive, effective April 2, 2026. Zalewski was most recently a partner and chair of the Healthcare and Life Sciences practice at Day
03-20 19:03
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Aquestive Therapeutics appoints Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, succeeding Lori J. Braender, who will continue as Corporate Secretary. Zalewski, with extensive experience in life sciences law, will support the company's mission to advance Anaphylm, the first oral epinephrine rescue medication. Braender, after nearly eight years in her roles, will focus on corporate governance. The c...
03-20 11:00
Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Matthew J. Greenhawt
Aquestive Therapeutics Files Initial Beneficial Ownership Statement for Chief Medical Officer Matthew J. Greenhawt Aquestive Therapeutics Inc. filed an initial statement of beneficial ownership for Matthew J. Greenhawt, Chief Medical Officer. The full filing can be accessed through the link below. D
03-11 21:20
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Aquestive Therapeutics announced an inducement grant for CMO Matthew Greenhawt under its 2022 Equity Inducement Plan. The grant includes 75,000 RSUs and 50,000 non-qualified stock options, each vesting 25% after the first and second anniversaries, and 50% on the third. The options have a 10-year term and an exercise price based on March 9, 2026 closing price. The awards were approved by the independent Compensation Committee. Aquestive specialize...
03-09 20:01
AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability
Aquestive Therapeutics, Inc. (AQST) has disclosed a new risk, in the Innovation...
03-06 14:01
